Comparative evaluation of hERG potassium channel blockade by antipsychotics

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 7, 2007, Pages 457-465

  Silvestre, Jordi S ^a,b   Prous, J R ^a  

^a Prous Institute for Biomedical Research   (Spain)

^b PROUS SCIENCE   (Spain)

Author keywords

Antipsychotic drugs; Arrhythmogenic risk; Electrophysiology; hERG blockade; Human ether a go go related gene; Patch clamp; QT interval prolongation; Torsade de pointes; Ventricular arrhythmia

Indexed keywords

AMISULPRIDE; AMOXAPINE; ARIPIPRAZOLE; BENPERIDOL; BENZAMIDE DERIVATIVE; BROMPERIDOL; BUTYROPHENONE DERIVATIVE; DIBENZOXAZEPINE DERIVATIVE; DIPHENYLBUTYLPIPERIDINE DERIVATIVE; FLUPENTIXOL; FLUPHENAZINE; LEVOMEPROMAZINE; LOXAPINE SUCCINATE; MELPERONE; NEUROLEPTIC AGENT; PENFLURIDOL; PERICIAZINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; PIPAMPERONE; POTASSIUM CHANNEL HERG; PROCHLORPERAZINE MALEATE; REMOXIPRIDE; SULPIRIDE; THIORIDAZINE; TRIFLUPROMAZINE; ZOTEPINE; ZUCLOPENTHIXOL;

ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; PATCH CLAMP; QT INTERVAL;

ANTIPSYCHOTIC AGENTS; ASTEMIZOLE; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; POTASSIUM CHANNEL BLOCKERS;

EID: 36349007027     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2007.29.7.1119172     Document Type: Article

References (87)

1. Sanguinetti, M.C., Jiang, C., Curran, M.E., Keating, M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: hERG encodes the IKr potassium channel. Cell 1995, 81, 299-307.
2. Trudeau, M.C., Warmke, J.W., Ganetzky, B., Robertson, G.A. hERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995, 269, 92-5.
3. Keating, M.T., Sanguinetti, M.C. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001, 104, 569-80.
4. Moss, A.J. The QT interval and torsade de pointes. Drug Saf 1999, 21 (Suppl 1), 5-10.
5. Viskin, S. Long QT syndromes and torsade de pointes. Lancet 1999, 354, 1625-33.
6. Roden, D.M. Drug-induced prolongation of the QT interval. N Engl J Med 2004, 350, 1013-22.
7. Haverkamp, W., Breithardt, G., Camm, A.J. et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000, 21, 1216-31.
8. Belardinelli, L., Antzelevitch, C., Vos, M.A. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003, 24, 619-25.
9. Stollberger, C., Huber, J.O., Finsterer, J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005, 20, 243-51.
10. De Ponti, F., Poluzzi, E., Montanaro, N. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: A call for consensus. Eur J Clin Pharmacol 2001, 57, 185-209.
11. Redfern, W.S., Carlsson, L., Davis, A.S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 2003, 58, 32-45.
12. Drugs that prolong the QT interval and/or induce Torsades de Pointes ventricular arrhythmia. Arizona CERT, www.torsades.org. Last accessed on 3-1-2006.
13. Witchel, H.J., Hancox, J.C., Nutt, D.J. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003, 23, 58-77.
14. Pacher, P., Kecskemeti, V. Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns? Curr Pharm Des 2004, 10, 2463-75.
15. Titier, K., Girodet, P.O., Verdoux, H. et al. Atypical antipsychotics: From potassium channels to torsade de pointes and sudden death. Drug Saf 2005, 28, 35-51.
16. Kr potassium channel as pharmacological target: Structure, function, regulation, and clinical applications. Curr Pharm Des 2006, 12, 2271-83.
17. De Bruin, M.L., Pettersson, M., Meyboom, R.H., Hoes, A.W., Leufkens, H.G. Anti-hERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005, 26, 590-7.
18. Cavero, I., Mestre, M., Guillon, J.M., Crumb, W. Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000, 1, 947-73.
19. De Ponti, F., Poluzzi, E., Cavalli, A., Recanatini, M., Montanaro, N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes an overview. Drug Safety 2002, 25, 263-86.
20. Tseng, G.N. 1(Kr): The hERG channel. J Mol Cell Cardiol 2001, 33, 835-49.
21. Lasser, K.E., Allen, P.D., Woolhandler, S.J., Himmelstein, D.U., Wolfe, S.M., Bor, D.H. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002, 287, 2215-20.
22. Fermini, B., Fossa, A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2003, 2, 439-47.
23. Fenichel, R.R., Malik, M., Antzelevitch, C. et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004, 15, 475-95.
24. Curtis, L.H., Ostbye, T., Sendersky, V. et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003, 114, 135-41.
25. Straus, S.M., Bleumink, G.S., Dieleman, J.P. et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004, 164, 1293-7.
26. Abdelmawla, N., Mitchell, A.J. Sudden cardiac death and antipsychotics, Part 1: Risk factors and mechanisms. Adv Psychiatr Treat 2006, 12, 35-44.
27. Glassman, A.H. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005, 66 (Suppl 6), 5-10.
28. Harrigan, E.P., Miceli, J.J., Anziano, R. et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004, 24, 62-9.
29. Taylor, D.M. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003, 107, 85-95.
30. Agelink, M.W., Majewski, T., Wurthmann, C. et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001, 21, 8-13.
31. Testai, L., Bianucci, A.M., Massarelli, I. et al. Torsadogenic cardiotoxicity of antipsychotic drugs: A structural feature, potentially involved in the interaction with cardiac hERG potassium channels. Curr Med Chem 2004, 11, 2691-706.
32. Buckley, N.A., Whyte, I.M., Dawson, A.H. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995, 33, 199-204.
33. Haddad, P.M., Anderson, I.M. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002, 62, 1649-71.
34. Abdelmawla, N., Mitchell, A.J. Sudden cardiac death and antipsychotics, Part 2: Monitoring and prevention. Adv Psychiatr Treat 2006, 12, 100-9.
35. Lindstrom, E., Farde, L., Eberhard, J., Haverkamp, W. QTc interval prolongation and antipsychotic drug treatments: Focus on sertindole. Int J Neuropsychopharmacol 2005, 8, 615-29.
36. Taylor, D. Ziprasidone in the management of schizophrenia: The QT interval issue in context. CNS Drugs 2003, 17, 423-30.
37. Agelink, M.W. Prolongation of QTc interval and antipsychotics. Am J Psychiatry 2002, 159, 1063.
38. Crumb, W.J., Jr., Ekins, S., Sarazan, R.D. et al. Effects of antipsychotic drugs on I(to), I(Na), I(sus), I(Kl), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res 2006, 23, 1133-43.
39. Kongsamut, S., Kang, J., Chen, X.L., Roehr, J., Rampe, D. A comparison of the receptor binding and hERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002, 450, 37-41.
40. Ekins, S., Crumb, W.J., Sarazan, R.D., Wikel, J.H., Wrighton, S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 2002, 301, 427-34.
41. Schmid, C., Grohmann, R., Engel, R.R., Ruther, E., Kropp, S. Cardiac adverse effects associated with psychotropic drugs. Pharmacopsychiatry 2004, 37 (Suppl 1), S65-9.
42. Reilly, J.G., Ayis, S.A., Ferner, I.N., Jones, S.J., Thomas, S.H. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000, 355, 1048-52.
43. Sadanaga, T., Sadanaga, F., Yao, H., Fujishima, M. Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: Significance of bradycardia-dependent QT prolongation. J Electrocardiol 2004, 37, 267-73.
44. Kim, M.D., Eun, S.Y., Jo, S.H. Blockade of hERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine. Eur J Pharmacol 2006, 544, 82-90.
45. Bains, W., Basman, A., White, C. hERG binding specificity and binding site structure: Evidence from a fragment-based evolutionary computing SAR study. Prog Biophys Mol Biol 2004, 86, 205-33.
46. Wood, C., Williams, C., Waldron, G.J. Patch clamping by numbers. Drug Discov Today 2004, 9, 434-41.
47. Witchel, H.J., Milnes, J.T., Mitcheson, J.S., Hancox, J.C. Trouble-shooting problems with in vitro screening of drugs for QT interval prolongation using hERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Methods 2002, 48, 65-80.
48. Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., De Ponti, F. QT prolongation through hERG K(+) channel blockade: Current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005, 25, 133-66.
49. Chiu, P.J., Marcoe, K.F., Bounds, S.E. et al. Validation of a [3H]astemizole binding assay in HEK293 cells expressing hERG K+ channels. J Pharmacol Sci 2004, 95, 311-9.
50. Zhou, Z., Gong, Q., Ye, B. et al. Properties of hERG channels stably expressed in HEK293 cells studied at physiological temperature. Biophys J 1998, 74, 230-41.
51. Dubin, A.E., Nasser, N., Rohrbacher, J. et al. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J Biomol Screen 2005, 10, 168-81.
52. Katchman, A.N., Koerner, J., Tosaka, T., Woosley, R.L., Ebert, S.N. Comparative evaluation of hERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 2006, 316, 1098-106.
53. Aronov, A.M. Predictive in silico modeling for hERG channel blockers. Drug Discov Today 2005, 10, 149-55.
54. Bont, L., Bosker, H.A., Brus, F., Yska, J.P., Bosch, F.H. Torsade de pointes after pipamperone intoxication. Pharm World Sci 1998, 20, 137.
55. Hui, W.K., Mitchell, L.B., Kavanagh, K.M. et al. Melperone: Electrophysiologic and antiarrhythmic activity in humans. J Cardiovasc Pharmacol 1990, 15, 144-9.
56. Drolet, B., Zhang, S., Deschenes, D. et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 1999, 10, 1597-604.
57. Haddad, P.M., Anderson, I.M. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002, 62, 1649-71.
58. Lischke, V., Behne, M., Doelken, P. et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994, 79, 983-6.
59. Hennessy, S., Bilker, W.B., Knauss, J.S. et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: Cohort study using administrative data. BMJ 2002, 325, 1070.
60. Straus, S.M., Sturkenboom, M.C., Bleumink, G.S. et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005, 26, 2007-12.
61. Hassaballa, H.A., Balk, R.A. Torsade de pointes associated with the administration of intravenous haloperidol: A review of the literature and practical guidelines for use. Expert Opin Drug Saf 2003, 2, 543-7.
62. Sultana, A., McMonagle, T. Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev CD001949 (2000).
63. Fulop, G., Phillips, R.A., Shapiro, A.K. et al. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987, 144, 673-5.
64. Soares, B.G., Lima, M.S. Penfluridol for schizophrenia. Cochrane Database Syst Rev CD002923 (2006).
65. Alvarez-Mena, S.C., Frank, M.J. Phenothiazine-induced T-wave abnormalities. Effects of overnight fasting. JAMA 1973, 224, 1730-3.
66. Ban, T.A., Jean, A.S. Electrocardiographic changes induced by phenothiazine drugs. Am Heart J 1965, 70, 575-6.
67. Raj, M.V.J., Benson, R. Phenothiazines and the electrocardiogram. Postgrad Med J 1975, 51, 65-8.
68. Kumar, A., Strech, D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev CD005474 (2005).
69. Chong, S.A., Mythily, Lum, A., Goh, H.Y., Chan, Y.H. Prolonged QTc intervals in medicated patients with schizophrenia. Hum Psychopharmacol 2003, 18, 647-9.
70. Reilly, J.G., Ayis, S.A., Ferrier, I.N., Jones, S.J., Thomas, S.H. Thioridazine and sudden unexplained death in psychiatric inpatients. Br J Psychiatry 2002, 180, 515-22.
71. Glassman, A.H., Preud'homme, X.A. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993, 54 (Suppl), 16-22.
72. Apiquian, R., Fresan, A., Ulloa, R.E. et al. Amoxapine as an atypical antipsychotic: A comparative study vs risperidone. Neuropsychopharmacology 2005, 30, 2236-44.
73. Fenton, M., Murphy, B., Wood, J. et al. Loxapine for schizophrenia. Cochrane Database Syst Rev CD001943 (2000).
74. Vieweg, W.V., Yazel, J.J., Ballenger, J.C. Tricyclic antidepressant use in a patient with bundle branch blocks and ventricular ectopy. J Clin Psychiatry 1984, 45, 353-5.
75. Munger, M.A., Effron, B.A. Amoxapine cardiotoxicity. Ann Emerg Med 1988, 17, 274-8.
76. Potkin, S.G., Saha, A.R., Kujawa, M.J. et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003, 60, 681-90.
77. Fenton, M., Morris, S., De Silva, P. et al. Zotepine for schizophrenia. Cochrane Database Syst Rev CD001948 (2000).
78. El Sayeh, H.G., Morganti, C., Adams, C.E. Aripiprazole for schizophrenia. Systematic review. Br J Psychiatry 2006, 189, 102-8.
79. Coulouvrat, C., Dondey-Nouvel, L. Safety of amisulpride (Solian): A review of 11 clinical studies. Int Clin Psychopharmacol 1999, 14, 209-18.
80. Mota, N.E., Lima, M.S., Soares, B.G. Amisulpride for schizophrenia. Cochrane Database Syst Rev CD001357 (2002).
81. Soares, B.G., Fenton, M., Chue, P. Sulpiride for schizophrenia. Cochrane Database Syst Rev CD001162 (2000).
82. Holm, A.C., Edsman, I., Lundberg, T., Odlind, B. Tolerability of remoxipride in the long term treatment of schizophrenia. An overview. Drug Saf 1993, 8, 445-56.
83. Lindstrom, L., Besev, G., Sterling, G., Widerlov, E. An open study of remoxipride, a benzamide derivative, in schizophrenia. Psychopharmacology (Berl) 1985, 86, 241-3.
84. Pedrosa, G.F., Grohmann, R., Ruther, E. Asymptomatic bradycardia associated with amisulpride. Pharmacopsychiatry 2001, 34, 259-61.
85. Isbister, G.K., Murray, L., John, S. et al. Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. Med J Aust 2006, 184, 354-6.
86. Su, K.P., Shen, W.W., Chuang, C.L., Chen, K.P., Chen, C.C. A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol. Schizophr Res 2003, 59, 93-4.
87. Huang, B.H., Hsia, C.P., Chen, C.Y. Sulpiride induced torsade de pointes. Int J Cardiol 2007, 118, e100-2.